Human Tetanus Immunoglobulin (HTIG) remains a cornerstone in the global medical arsenal against Clostridium tetani infections. Unlike active vaccination with Tetanus Toxoid (TT), which requires time for the body to mount an immune response, HTIG provides immediate, passive immunity. This "Information Gain" is critical for healthcare providers: HTIG is indispensable for managing category III wounds in patients with uncertain or inadequate immunization history.
Jiangxi Serum Pharma Industries Co., Ltd. has dedicated nearly a decade to bridging the gap between high-end biological manufacturing and global accessibility. As a premier Human Tetanus Immunoglobulin supplier, we integrate E-E-A-T principles—Expertise in plasma fractionation, Authoritativeness in WHO-standard compliance, and Trustworthiness through transparent supply chain logistics.
The global demand for HTIG is projected to grow steadily, driven by rising surgical procedures and trauma cases in emerging economies. However, the industry faces a significant bottleneck: the availability of high-titer donor plasma.
We solve the global HTIG shortage by diversifying plasma sources and optimizing the cold-chain logistics network, ensuring that biological integrity is maintained from the laboratory to the rural clinic.
Navigating the USP, BP, and EP pharmacopeia requirements. Our products are pre-vetted for international registration, reducing the time-to-market for regional distributors.
Strategic stock management for NGOs and Ministry of Health (MoH) tenders, providing tiered pricing and flexible shipment schedules to prevent stock-outs during health crises.
Manufacturing HTIG is a high-precision process. At Jiangxi Serum Pharma, our partners utilize the Cohn Cold Ethanol Fractionation method, enhanced by modern chromatography techniques to maximize purity and minimize adverse reactions.
Utilization of Solvent/Detergent treatment and 20nm nanofiltration ensures the highest level of viral safety, exceeding standard GMP requirements.
Implementation of advanced protein stabilizers allows for better thermal stability, a crucial factor for localized support in tropical or remote regions.
We are currently monitoring the development of recombinant human monoclonal antibodies (mAbs) to eventually supplement plasma-derived products, ensuring a sustainable future for tetanus treatment.
Effective Human Tetanus Immunoglobulin distribution requires more than just shipping a product; it requires localized expertise. We provide comprehensive documentation support (CTD format) to facilitate local MOH registrations.
Guidelines for emergency room use, especially in neonatal tetanus prevention and post-surgical care for trauma patients.
Every batch undergoes rigorous quality control, providing 100% traceability from donor to vial.
Active monitoring and localized reporting systems to ensure long-term safety and efficacy in various demographic populations.
Established in 2017, Jiangxi Serum Pharma Industries Co., Ltd. has become a professional beacon in the export of biological products and Western medicines. Our portfolio extends beyond HTIG to include vaccines, raw materials, intermediates, and medical consumables.
Currently, we cooperate with partners on the customization of Pre-Mix, Co-Crystallization, and Bio-Fermentation services. Our annual sales exceeding $10,000,000 US dollars is a testament to our reliability and global reach.
